1
|
Gopalakrishnapillai A, Correnti CE, Pilat K, Lin I, Chan MK, Bandaranayake AD, Mehlin C, Kisielewski A, Hamill D, Kaeding AJ, Meshinchi S, Olson JM, Kolb EA, Barwe SP. Immunotherapeutic Targeting of Mesothelin Positive Pediatric AML Using Bispecific T Cell Engaging Antibodies. Cancers (Basel) 2021; 13:cancers13235964. [PMID: 34885074 PMCID: PMC8657033 DOI: 10.3390/cancers13235964] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2021] [Revised: 11/23/2021] [Accepted: 11/24/2021] [Indexed: 12/20/2022] Open
Abstract
Simple Summary Immunotherapy development in pediatric AML has been slow due to the paucity of validated AML-specific targets. We recently identified mesothelin (MSLN) as a therapeutic target in pediatric AML. Mice receiving T cell engaging bispecific antibodies (BsAbs) targeting MSLN and CD3 achieved complete remission and durable responses in two MSLN-positive patient-derived xenograft (PDX) models. This is a first report showing MSLN-targeting BsAbs are a viable immunotherapy for MSLN-positive pediatric AML. Abstract Advances in the treatment of pediatric AML have been modest over the past four decades. Despite maximally intensive therapy, approximately 40% of patients will relapse. Novel targeted therapies are needed to improve outcomes. We identified mesothelin (MSLN), a well-validated target overexpressed in some adult malignancies, to be highly expressed on the leukemic cell surface in a subset of pediatric AML patients. The lack of expression on normal bone marrow cells makes MSLN a viable target for immunotherapies such as T-cell engaging bispecific antibodies (BsAbs) that combine two distinct antibody-variable regions into a single molecule targeting a cancer-specific antigen and the T-cell co-receptor CD3. Using antibody single-chain variable region (scFv) sequences derived from amatuximab-recognizing MSLN, and from either blinatumomab or AMG330 targeting CD3, we engineered and expressed two MSLN/CD3-targeting BsAbs: MSLNAMA-CD3L2K and MSLNAMA-CD3AMG, respectively. Both BsAbs promoted T-cell activation and reduced leukemic burden in MV4;11:MSLN xenografted mice, but not in those transplanted with MSLN-negative parental MV4;11 cells. MSLNAMA-CD3AMG induced complete remission in NTPL-146 and DF-5 patient-derived xenograft models. These data validate the in vivo efficacy and specificity of MSLN-targeting BsAbs. Because prior MSLN-directed therapies appeared safe in humans, MSLN-targeting BsAbs could be ideal immunotherapies for MSLN-positive pediatric AML patients.
Collapse
Affiliation(s)
- Anilkumar Gopalakrishnapillai
- Nemours Centers for Childhood Cancer Research & Cancer and Blood Disorders, Alfred I. duPont Hospital for Children, Wilmington, DE 19803, USA; (A.G.); (A.K.); (D.H.); (E.A.K.)
| | - Colin E. Correnti
- Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; (C.E.C.); (K.P.); (I.L.); (M.K.C.); (A.D.B.); (C.M.); (A.J.K.); (S.M.); (J.M.O.)
| | - Kristina Pilat
- Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; (C.E.C.); (K.P.); (I.L.); (M.K.C.); (A.D.B.); (C.M.); (A.J.K.); (S.M.); (J.M.O.)
| | - Ida Lin
- Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; (C.E.C.); (K.P.); (I.L.); (M.K.C.); (A.D.B.); (C.M.); (A.J.K.); (S.M.); (J.M.O.)
| | - Man Kid Chan
- Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; (C.E.C.); (K.P.); (I.L.); (M.K.C.); (A.D.B.); (C.M.); (A.J.K.); (S.M.); (J.M.O.)
| | - Ashok D. Bandaranayake
- Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; (C.E.C.); (K.P.); (I.L.); (M.K.C.); (A.D.B.); (C.M.); (A.J.K.); (S.M.); (J.M.O.)
| | - Christopher Mehlin
- Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; (C.E.C.); (K.P.); (I.L.); (M.K.C.); (A.D.B.); (C.M.); (A.J.K.); (S.M.); (J.M.O.)
| | - Anne Kisielewski
- Nemours Centers for Childhood Cancer Research & Cancer and Blood Disorders, Alfred I. duPont Hospital for Children, Wilmington, DE 19803, USA; (A.G.); (A.K.); (D.H.); (E.A.K.)
| | - Darcy Hamill
- Nemours Centers for Childhood Cancer Research & Cancer and Blood Disorders, Alfred I. duPont Hospital for Children, Wilmington, DE 19803, USA; (A.G.); (A.K.); (D.H.); (E.A.K.)
| | - Allison J. Kaeding
- Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; (C.E.C.); (K.P.); (I.L.); (M.K.C.); (A.D.B.); (C.M.); (A.J.K.); (S.M.); (J.M.O.)
| | - Soheil Meshinchi
- Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; (C.E.C.); (K.P.); (I.L.); (M.K.C.); (A.D.B.); (C.M.); (A.J.K.); (S.M.); (J.M.O.)
| | - James M. Olson
- Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; (C.E.C.); (K.P.); (I.L.); (M.K.C.); (A.D.B.); (C.M.); (A.J.K.); (S.M.); (J.M.O.)
| | - Edward Anders Kolb
- Nemours Centers for Childhood Cancer Research & Cancer and Blood Disorders, Alfred I. duPont Hospital for Children, Wilmington, DE 19803, USA; (A.G.); (A.K.); (D.H.); (E.A.K.)
| | - Sonali P. Barwe
- Nemours Centers for Childhood Cancer Research & Cancer and Blood Disorders, Alfred I. duPont Hospital for Children, Wilmington, DE 19803, USA; (A.G.); (A.K.); (D.H.); (E.A.K.)
- Correspondence: ; Tel.: +1-302-651-6542
| |
Collapse
|